Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Interest & Investment Income (2016 - 2021)

ImmunityBio (IBRX) has disclosed Interest & Investment Income for 7 consecutive years, with -$8.5 million as the latest value for Q2 2021.

  • On a quarterly basis, Interest & Investment Income fell 11424.0% to -$8.5 million in Q2 2021 year-over-year; TTM through Jun 2021 was $1.0 million, a 12.94% increase, with the full-year FY2020 number at $1.2 million, down 24.95% from a year prior.
  • Interest & Investment Income was -$8.5 million for Q2 2021 at ImmunityBio, down from $8.9 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $8.9 million in Q1 2021 to a low of -$8.5 million in Q2 2021.
  • A 5-year average of $505111.1 and a median of $476000.0 in 2018 define the central range for Interest & Investment Income.
  • Biggest YoY gain for Interest & Investment Income was 11366.67% in 2021; the steepest drop was 11424.0% in 2021.
  • ImmunityBio's Interest & Investment Income stood at $1.8 million in 2017, then plummeted by 76.42% to $415000.0 in 2018, then decreased by 23.37% to $318000.0 in 2019, then soared by 187.42% to $914000.0 in 2020, then plummeted by 1029.21% to -$8.5 million in 2021.
  • Per Business Quant, the three most recent readings for IBRX's Interest & Investment Income are -$8.5 million (Q2 2021), $8.9 million (Q1 2021), and $914000.0 (Q4 2020).